Lantheus Presents New Radiodiagnostic Data at 2026 SNMMI Meeting
Event summary
- Lantheus to present new radiodiagnostic data at the 2026 SNMMI Annual Meeting in Los Angeles.
- Poster presentation on June 1, 2026, focusing on PSMA-PET for prostate cancer management.
- Oral presentation on June 2, 2026, on diagnostic performance of 18F-GP1 PET/CT for deep vein thrombosis.
The big picture
Lantheus' presentations at the 2026 SNMMI Annual Meeting highlight its focus on advancing radiodiagnostic technologies, particularly in oncology and vascular imaging. The company's emphasis on innovative diagnostic tools aligns with broader industry trends towards precision medicine and early disease detection. With a strong presence in the radiopharmaceutical sector, Lantheus aims to reinforce its position as a key player in medical imaging solutions.
What we're watching
- Clinical Validation
- How the new data will impact the adoption of Lantheus' radiodiagnostic tools in clinical practice.
- Market Differentiation
- Whether Lantheus can sustain its leadership position in the radiopharmaceutical space with these advancements.
- Regulatory Approvals
- The pace at which regulatory approvals for these diagnostic tools will progress post-presentation.
Related topics